KRT16 antibody (C-Term)
Quick Overview for KRT16 antibody (C-Term) (ABIN7877412)
Target
See all KRT16 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- C-Term
-
Purpose
- KRT16 Antibody / Cytokeratin 16
-
Purification
- Protein A/G affinity
-
Immunogen
- A recombinant protein fragment from the C-terminal region was used as the immunogen for the KRT16 antibody.
-
Isotype
- IgG1, kappa
-
-
-
-
Application Notes
- Optimal dilution of the KRT16 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the KRT16 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- KRT16 (Keratin 16 (KRT16))
-
Alternative Name
- KRT16
-
Background
- Cytokeratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I Cytokeratins (Cytokeratins 9 to 23) and one type II Cytokeratins (keratins 1 to 8). The cytokeratin proteins play a critical role in differentiation, as well as tissue specialization and function, to maintain the overall structural integrity of epithelial cells. Cytokeratins are also useful markers in identifying the origin of metastatic tumors. Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in non-invasive breast carcinomas and normal breast tissue.
-
UniProt
- P08779
Target
-